Astrana Health (NASDAQ:ASTH – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Sunday.
ASTH has been the subject of a number of other research reports. Truist Financial lifted their price target on Astrana Health from $47.00 to $55.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Weiss Ratings raised Astrana Health from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 1st. BTIG Research raised their price objective on Astrana Health from $50.00 to $65.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Needham & Company LLC lifted their target price on Astrana Health from $30.00 to $41.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Finally, Barclays lifted their target price on Astrana Health from $50.00 to $53.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $49.43.
Get Our Latest Stock Report on ASTH
Astrana Health Trading Down 2.6%
Astrana Health (NASDAQ:ASTH – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.46. Astrana Health had a net margin of 1.05% and a return on equity of 10.30%. The firm had revenue of $972.52 million for the quarter, compared to analyst estimates of $985.62 million. During the same period in the previous year, the company earned $0.19 earnings per share. The business’s quarterly revenue was up 48.5% compared to the same quarter last year. Analysts predict that Astrana Health will post 1.18 EPS for the current year.
Institutional Investors Weigh In On Astrana Health
Several hedge funds have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio acquired a new stake in Astrana Health during the 2nd quarter worth about $51,000. Great Lakes Advisors LLC acquired a new position in shares of Astrana Health in the 2nd quarter valued at about $832,000. Diamond Hill Capital Management LLC Investment Advisor acquired a new position in shares of Astrana Health in the 2nd quarter valued at about $22,088,000. Bank of New York Mellon Corp purchased a new stake in shares of Astrana Health in the second quarter worth about $10,902,000. Finally, Bank of America Corp DE boosted its stake in shares of Astrana Health by 13.3% in the first quarter. Bank of America Corp DE now owns 574,729 shares of the company’s stock worth $14,092,000 after buying an additional 67,628 shares during the last quarter. 52.77% of the stock is owned by hedge funds and other institutional investors.
About Astrana Health
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.
Featured Articles
- Five stocks we like better than Astrana Health
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter.
